Physician profile
Wanda Lewis
NPI 1245252782
$935.49
in general payments reported to CMS, 2019-2025
15 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $86.47 · 2023: $45.70 · 2024: $49.43 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $239.46 | 2019-2025 | Ozempic |
| Lilly USA, LLC | $142.69 | 2019-2025 | Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $78.19 | 2025 | Voquezna |
| Pfizer INC. | $75.93 | 2019-2025 | |
| Amgen INC. | $73.56 | 2025 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.55 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $66.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.31 | 2019-2025 | Breztri |
| Insmed, INC. | $33.95 | 2025 | Brinsupri, Arikayce |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.04 | 2025 | Caplyta |
| Exact Sciences Corporation | $24.79 | 2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $16.59 | 2019 | |
| Glaxosmithkline, LLC. | $15.50 | 2023 | Trelegy Ellipta, Shingrix |
| Chiesi USA, INC. | $15.26 | 2019 | |
| Philips North America LLC | $14.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.